| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Role of AMP-activated protein kinase in mechanism of metformin action. | J Clin Invest | 2001 | 23.21 |
| 2 | Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. | Diabetes | 1997 | 2.10 |
| 3 | Recognition of lysosomal glycosidases in vivo inhibited by modified glycoproteins. | Nature | 1976 | 1.46 |
| 4 | Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. | Endocrinology | 1998 | 1.16 |
| 5 | PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver. | Biochem Biophys Res Commun | 2000 | 0.90 |
| 6 | High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. | Eur J Pharmacol | 2001 | 0.89 |
| 7 | Conformation and activity of tetrahydrofuran lignans and analogues as specific platelet activating factor antagonists. | J Med Chem | 1986 | 0.77 |